{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:35:48Z","timestamp":1791722148389,"version":"4.3.4"},"reference-count":31,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,9,2]]},"DOI":"10.1248\/bpb.b25-00392","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T22:08:15Z","timestamp":1756764495000},"page":"1325-1334","source":"Crossref","is-referenced-by-count":2,"title":["Development of a Specific Competitive ELISA for Plasma Adropin Levels and Its Application to Investigating Energy Homeostasis in Mice"],"prefix":"10.1248","volume":"48","author":[{"given":"Noriko","family":"Tagawa","sequence":"first","affiliation":[{"name":"Laboratory of Epidemiology and Prevention, Kobe Pharmaceutical University, Kobe 685\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890\u20138544, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Asakawa","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890\u20138544, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Laboratory of Epidemiology and Prevention, Kobe Pharmaceutical University, Kobe 685\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Tanaka-Mizuno","sequence":"additional","affiliation":[{"name":"Laboratory of Epidemiology and Prevention, Kobe Pharmaceutical University, Kobe 685\u20138558, Japan"},{"name":"Data Science and Innovation Research Promotion Center, Shiga University, 1\u20131\u20131 Baba, Hikone, Shiga 522\u20138522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, Kousoulas KG, Rogers PM, Kesterson RA, Thearle M, Ferrante AW Jr, Mynatt RL, Burris TP, Dong JZ, Halem HA, Culler MD, Heisler LK, Stephens JM, Butler AA. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. <i>Cell Metab.<\/i>, <b>8<\/b>, 468\u2013481 (2008).","DOI":"10.1016\/j.cmet.2008.10.011"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kumar KG, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, Culler MD, Mynatt RL, Butler AA. Adropin deficiency is associated with increased adiposity and insulin resistance. <i>Obesity (Silver Spring)<\/i>, <b>20<\/b>, 1394\u20131402 (2012).","DOI":"10.1038\/oby.2012.31"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, Altas Y, Aydin S, Aydin S. Deficiency of a new protein associated with cardiac syndrome X; called adropin. <i>Cardiovasc. Ther.<\/i>, <b>31<\/b>, 174\u2013178 (2013).","DOI":"10.1111\/1755-5922.12025"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Alzoughool F, Al-Zghoul MB. Optimal therapeutic adropin dose intervention in mice and rat animal models: a systematic review. <i>Vet. World.<\/i>, <b>14<\/b>, 1426\u20131429 (2021).","DOI":"10.14202\/vetworld.2021.1426-1429"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ghoshal S, Banerjee S, Zhang J, Niehoff ML, Farr SA, Butler AA. Adropin transgenesis improves recognition memory in diet-induced obese LDLR-deficient C57BL\/6J mice. <i>Peptides<\/i>, <b>146<\/b>, 170678 (2021).","DOI":"10.1016\/j.peptides.2021.170678"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Hasanpour-Segherlou Z, Butler AA, Candelario-Jalil E, Hoh BL. Role of the unique secreted peptide adropin in various physiological and disease states. <i>Biomolecules<\/i>, <b>14<\/b>, 1613 (2024).","DOI":"10.3390\/biom14121613"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Stein LM, Yosten GL, Samson WK. Adropin acts in brain to inhibit water drinking: potential interaction with the orphan G protein-coupled receptor, GPR19. <i>Am. J. Physiol. Regul. Integr. Comp. Physiol.<\/i>, <b>310<\/b>, R476\u2013R480 (2016).","DOI":"10.1152\/ajpregu.00511.2015"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M. Adropin as a fat-burning hormone with multiple functions-review of a decade of research. <i>Molecules<\/i>, <b>25<\/b>, 549 (2020).","DOI":"10.3390\/molecules25030549"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Soltani S, Kolahdouz-Mohammadi R, Aydin S, Yosaee S, Clark CCT, Abdollahi S. Circulating levels of adropin and overweight\/obesity: a systematic review and meta-analysis of observational studies. <i>Hormones (Athens)<\/i>, <b>21<\/b>, 15\u201322 (2022).","DOI":"10.1007\/s42000-021-00331-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ali II, D\u2019Souza C, Singh J, Adeghate E. Adropin\u2019s role in energy homeostasis and metabolic disorders. <i>Int. J. Mol. Sci.<\/i>, <b>23<\/b>, 8318 (2022).","DOI":"10.3390\/ijms23158318"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Soltani S, Beigrezaei S, Malekahmadi M, Clark CCT, Abdollahi S. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies. <i>BMC Endocr. Disord.<\/i>, <b>23<\/b>, 73 (2023).","DOI":"10.1186\/s12902-023-01327-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Lian W, Gu X, Qin Y, Zheng X. Elevated plasma levels of adropin in heart failure patients. <i>Intern. Med.<\/i>, <b>50<\/b>, 1523\u20131527 (2011).","DOI":"10.2169\/internalmedicine.50.5163"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Altincik A, Sayin O. Evaluation of the relationship between serum adropin levels and blood pressure in obese children. <i>J. Pediatr. Endocrinol. Metab.<\/i>, <b>28<\/b>, 1095\u20131100 (2015).","DOI":"10.1515\/jpem-2015-0051"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) D\u0105browski FA, Jarmu\u017cek P, Gondek A, Cudnoch-J\u0119drzejewska A, Bomba-Opo\u0144 D, Wielgo\u015b M. First and third trimester serum concentrations of adropin and copeptin in gestational diabetes mellitus and normal pregnancy. <i>Ginekol. Pol.<\/i>, <b>87<\/b>, 629\u2013634 (2016).","DOI":"10.5603\/GP.2016.0057"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kobayashi N. Development of sensitive and specific determination methods of bioactive compounds based on generation of high-performance antibodies. <i>Biol. Pharm. Bull.<\/i>, <b>48<\/b>, 475\u2013494 (2025).","DOI":"10.1248\/bpb.b25-00073"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Tagawa N, Ogura H, Miyawaki H, Asakawa A, Kato I. Intraperitoneal administration of nesfatin-1 stimulates glucagon-like peptide-1 secretion in fasted mice. <i>Mol. Med. Rep.<\/i>, <b>27<\/b>, 7 (2023).","DOI":"10.3892\/mmr.2022.12894"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Anwer T, Sharma M, Pillai KK, Iqbal M. Effect of <i>Withania somnifera<\/i> on insulin sensitivity in non-insulin-dependent diabetes mellitus rats. <i>Basic Clin. Pharmacol. Toxicol.<\/i>, <b>102<\/b>, 498\u2013503 (2008).","DOI":"10.1111\/j.1742-7843.2008.00223.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kumari D, Gautam J, Sharma V, Gupta SK, Sarkar S, Jana P, Singhal V, Babele P, Kamboj P, Bajpai S, Tandon R, Kumar Y, Dikshit M. Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL\/6J mice. <i>Heliyon<\/i>, <b>9<\/b>, e22051 (2023).","DOI":"10.1016\/j.heliyon.2023.e22051"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Banerjee S, Ghoshal S, Stevens JR, McCommis KS, Gao S, Castro-Sepulveda M, Mizgier ML, Girardet C, Kumar KG, Galgani JE, Niehoff ML, Farr SA, Zhang J, Butler AA. Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction. <i>J. Biol. Chem.<\/i>, <b>295<\/b>, 13753\u201313768 (2020).","DOI":"10.1074\/jbc.RA120.014381"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Singh A, de Araujo AM, Krieger JP, Vergara M, Ip CK, de Lartigue G. Demystifying functional role of cocaine- and amphetamine-related transcript (CART) peptide in control of energy homeostasis: A twenty-five year expedition. <i>Peptides<\/i>, <b>140<\/b>, 170534 (2021).","DOI":"10.1016\/j.peptides.2021.170534"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Chen S, Zeng K, Liu QC, Guo Z, Zhang S, Chen XR, Lin JH, Wen JP, Zhao CF, Lin XH, Gao F. Adropin deficiency worsens HFD-induced metabolic defects. <i>Cell Death Dis.<\/i>, <b>8<\/b>, e3008 (2017).","DOI":"10.1038\/cddis.2017.362"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Thapa D, Xie B, Zhang M, Stoner MW, Manning JR, Huckestein BR, Edmunds LR, Mullett SJ, McTiernan CF, Wendell SG, Jurczak MJ, Scott I. Adropin treatment restores cardiac glucose oxidation in pre-diabetic obese mice. <i>J. Mol. Cell. Cardiol.<\/i>, <b>129<\/b>, 174\u2013178 (2019).","DOI":"10.1016\/j.yjmcc.2019.02.012"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Chen X, Chen S, Shen T, Yang W, Chen Q, Zhang P, You Y, Sun X, Xu H, Tang Y, Mi J, Yang Y, Ling W. Adropin regulates hepatic glucose production <i>via<\/i> PP2A\/AMPK pathway in insulin-resistant hepatocytes. <i>FASEB J.<\/i>, <b>34<\/b>, 10056\u201310072 (2020).","DOI":"10.1096\/fj.202000115RR"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Moustafa A, Arisha AH. Swim therapy-induced tissue specific metabolic responses in male rats. <i>Life Sci.<\/i>, <b>262<\/b>, 118516 (2020).","DOI":"10.1016\/j.lfs.2020.118516"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Zapata RC, Meachem MD, Cardoso NC, Mehain SO, McMillan CJ, Snead ER, Chelikani PK. Differential circulating concentrations of adipokines, glucagon and adropin in a clinical population of lean, overweight and diabetic cats. <i>BMC Vet. Res.<\/i>, <b>13<\/b>, 85 (2017).","DOI":"10.1186\/s12917-017-1011-x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Stern JH, Smith GI, Chen S, Unger RH, Klein S, Scherer PE. Obesity dysregulates fasting-induced changes in glucagon secretion. <i>J. Endocrinol.<\/i>, <b>243<\/b>, 149\u2013160 (2019).","DOI":"10.1530\/JOE-19-0201"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Chen X, Maldonado E, DeFronzo RA, Tripathy D. Impaired suppression of glucagon in obese subjects parallels decline in insulin sensitivity and beta-cell function. <i>J. Clin. Endocrinol. Metab.<\/i>, <b>106<\/b>, 1398\u20131409 (2021).","DOI":"10.1210\/clinem\/dgab019"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ali II, D\u2019Souza C, Tariq S, Adeghate EA. Adropin is expressed in pancreatic islet cells and reduces glucagon release in diabetes mellitus. <i>Int. J. Mol. Sci.<\/i>, <b>25<\/b>, 9824 (2024).","DOI":"10.3390\/ijms25189824"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Butler AA, Havel PJ. Adropin and insulin resistance: Integration of endocrine, circadian, and stress signals regulating glucose metabolism. <i>Obesity<\/i>, <b>29<\/b>, 1799\u20131801 (2021).","DOI":"10.1002\/oby.23249"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Butler AA, Havel PJ. Adropin: a cardio-metabolic hormone in the periphery, a neurohormone in the brain? <i>Peptides<\/i>, <b>187<\/b>, 171391 (2025).","DOI":"10.1016\/j.peptides.2025.171391"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Wang Y, Li L, Chen L, Xia J, Wang T, Han L, Cao L, Wang Z, Xiao W, Jiang S. The influence of emodin succinyl ethyl ester on non-alcoholic steatohepatitis induced by a diet high in fructose, cholesterol, and fat in mice. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 978\u2013987 (2024).","DOI":"10.1248\/bpb.b23-00903"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00392\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:51:52Z","timestamp":1757130712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00392\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00392","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"b25-00392"}}